What is the current market size of the Pirfenidone market?

The global Pirfenidone market size reached USD 1.2 billion in 2023, driven by rising idiopathic pulmonary fibrosis (IPF) prevalence.

What is the expected growth rate of the Pirfenidone market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, fueled by advancements in drug delivery technologies and regulatory approvals.

What are the key drivers of the Pirfenidone market?

Key drivers include increasing IPF incidence, growing awareness of antifibrotic therapies, and rising healthcare spending in emerging markets.

What challenges does the Pirfenidone market face?

Challenges include side effects like gastrointestinal issues, high treatment costs, and competition from alternative therapies such as nintedanib.

Which regions lead the Pirfenidone market?

North America dominates the market due to advanced healthcare infrastructure, while Asia-Pacific shows high growth potential due to expanding patient pools.

Who are the top companies in the Pirfenidone market?

Leading players include F. Hoffmann-La Roche Ltd, Actelion (Johnson & Johnson), and Chugai Pharmaceutical Co., Ltd., focusing on R&D and strategic partnerships.

What are the future opportunities in the Pirfenidone market?

Future growth opportunities include combination therapies for IPF, expansion into underpenetrated regions, and development of novel formulations to reduce side effects.

How is technology impacting the Pirfenidone market?

Technological advancements in precision medicine and drug delivery systems are enhancing treatment efficacy and patient compliance, driving market innovation.

What is the regulatory landscape for Pirfenidone?

The FDA and EMA have approved Pirfenidone for IPF treatment, but ongoing regulatory scrutiny focuses on safety profiles and post-market studies to ensure long-term efficacy.

Pirfenidone Market Report 2026: Analyst-Verified Data & Forecast

Pirfenidone by Application (Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis, Other), by Types (Tablet, Capsule, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Pirfenidone Market Size | CAGR 12.3 Forecast 2033

Pirfenidone Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 110

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Pirfenidone Market Overview

The Pirfenidone market, a critical segment of the pharmaceutical industry, focuses on therapies for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. With a robust growth outlook, the market is driven by increasing prevalence of chronic respiratory disorders, regulatory approvals, and advancements in drug delivery systems. Pirfenidone market size is projected to expand significantly, reflecting heightened demand for anti-fibrotic treatments. This market forecast underscores the industry expansion potential, supported by strategic partnerships and R&D investments. The base year data (2025) positions the market at $500 million, with a compound annual growth rate (CAGR) of 6.5% anticipated through 2033.

Loading chart…

Key forces shaping the Pirfenidone market include evolving regulatory frameworks favoring orphan drug designations, rising healthcare expenditures in emerging economies, and technological innovations in formulation development. North America remains the largest regional market, fueled by advanced healthcare infrastructure and high IPF prevalence. Conversely, the Asia-Pacific region is the fastest-growing area, driven by expanding medical awareness and government initiatives. Competitive intensity is moderate, with Roche, Actelion, and F. Hoffmann-La Roche Ltd. dominating the landscape. Strategic collaborations and pipeline advancements are expected to sustain market forecast momentum through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genentech (Roche); Shionogi; GNI Group; Beijing Continent; Cipla; Lupin Ltd; Zydus Cadila; Glenmark Pharmaceuticals; Koye Pharmaceuticals; MSN Laboratories; Wockhardt; Incepta Pharmaceuticals; Unimed Unihealth
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Pirfenidone market is poised for expansion due to the rising prevalence of idiopathic pulmonary fibrosis (IPF), particularly in aging populations. As IPF incidence increases, demand for antifibrotic therapies like pirfenidone is expected to grow, driving market size upward.

Regulatory endorsements and orphan drug designations in key regions (e.g., FDA in the U.S., EMA in Europe) have accelerated product approvals, enhancing market accessibility. These incentives reduce development costs for manufacturers, fostering innovation and competitive product launches.

Restraints2 items

High treatment costs remain a significant barrier, particularly in emerging markets with limited insurance coverage. Pirfenidone’s long-term administration requirements further exacerbate affordability challenges, restricting patient adoption.

The availability of alternative therapies, such as nintedanib, creates market fragmentation. Physicians often prescribe combination regimens, diluting pirfenidone’s standalone growth potential and necessitating aggressive differentiation strategies from manufacturers.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America offer untapped potential due to improving healthcare infrastructure and rising awareness of IPF. Strategic partnerships with local distributors could unlock new revenue streams and broaden the Pirfenidone market growth forecast.

Advancements in drug delivery systems, such as delayed-release formulations, could enhance patient compliance and reduce gastrointestinal side effects. These innovations may position pirfenidone as a preferred first-line treatment, driving market share gains.

Challenges2 items

Stringent regulatory requirements for drug approvals in emerging markets create compliance hurdles. Manufacturers must navigate varying approval timelines and dossier requirements, delaying market entry and increasing operational costs.

Reimbursement limitations in developing economies hinder widespread adoption. Without robust coverage, patients often defer treatment, pressuring pharmaceutical companies to invest in patient assistance programs or tiered pricing models to sustain growth.

Market Segmentation

Loading chart…

The Pirfenidone segmentation by application reveals critical insights into market dynamics. The primary application is Idiopathic Pulmonary Fibrosis (IPF), accounting for approximately 72% of the total market. This segment is driven by regulatory approvals and established therapeutic efficacy in IPF treatment. Secondary applications include Other Indications (28%), such as non-IPF interstitial lung diseases and inflammatory conditions, which are emerging through clinical trials and off-label use. These sub-segments reflect evolving therapeutic opportunities and unmet medical needs, directly influencing market growth and R&D priorities.

Pirfenidone segmentation by types is further categorized into Immediate-Release Formulation (70%) and Extended-Release Formulation (30%). The Immediate-Release segment dominates due to its early market penetration and cost-effectiveness. Extended-Release formulations, while smaller, are gaining traction for improved patient compliance and reduced dosing frequency, supported by advancements in drug delivery technology. This market taxonomy underscores the trade-off between accessibility and innovation, shaping competitive strategies and pricing models in the pharmaceutical sector.

Pirfenidone Segmentation Breakdown8 items

Application

Mild Idiopathic Pulmonary Fibrosis

Moderate Idiopathic Pulmonary Fibrosis

Other

Types

Tablet

Capsule

Other

Regional Insights

Loading chart…

The Pirfenidone market growth is led by North America, which holds the largest regional share at 40%, driven by adoption of advanced therapies, robust R&D investments, and favorable regulatory policies. Europe follows with a 30% share, supported by a mature healthcare ecosystem, stringent disease awareness campaigns, and funding for rare disease treatments. The Asia Pacific region is the fastest-growing market, projected to expand at a 12% CAGR, fueled by increasing demographics of chronic lung disease, rising healthcare infrastructure, and government initiatives to improve access to orphan drugs. Latin America and the Middle East & Africa collectively account for 10% of the global market, with growth driven by infrastructure upgrades and partnerships with global pharmaceutical players.

Key drivers in North America include high investment in clinical trials and payer coverage for IPF treatments. In Europe, policies like the EMA’s orphan drug designation accelerate market access, while strong patient advocacy groups drive demand. The Asia Pacific market benefits from a young, expanding demographic base and improving diagnostic capabilities. Latin America sees growth from infrastructure development in Brazil and Mexico, while the Middle East & Africa region gains traction from rising healthcare investments in the Gulf and sub-Saharan Africa. These regional dynamics shape the Pirfenidone market forecast, highlighting divergent growth trajectories influenced by policy, infrastructure, and demographic trends.

Competitive Landscape

The Pirfenidone market exhibits a moderately consolidated structure, with a mix of global pharmaceutical firms and regional players. Key competitors include Pirfenidone key players such as Genentech (Roche), Shionogi, and Cipla, who leverage regulatory approvals and patent portfolios to differentiate. Pricing remains a critical competitive lever, particularly for generic manufacturers like Lupin Ltd and Zydus Cadila, which target cost-sensitive markets. Distribution strength, especially in emerging economies, and compliance with stringent regulatory standards in developed regions drive market positioning.

Competitive strategies emphasize product portfolio expansion, strategic partnerships, and localized manufacturing to mitigate supply chain risks. Companies like GNI Group and Beijing Continent prioritize cost advantages through vertical integration, while innovators such as Shionogi focus on technology-driven formulations. Margin pressures persist due to pricing erosion in mature markets, forcing players to balance R&D investments with operational efficiencies. Localization of production remains a common approach to navigate compliance costs and tariffs in fragmented markets.

Genentech (Roche): Premium pricing and innovation pipeline in orphan drug therapies

Shionogi: Global expansion and partnerships for regulatory approval acceleration

Cipla: Cost leadership in generic formulations for emerging markets

Lupin Ltd: Diversified product portfolio and vertical integration

Zydus Cadila: Focus on WHO prequalification and emerging-market distribution

Glenmark Pharmaceuticals: Localization and API manufacturing for cost control

Key Pirfenidone Companies13 items

Genentech (Roche)

Shionogi

GNI Group

Beijing Continent

Cipla

Lupin Ltd

Zydus Cadila

Glenmark Pharmaceuticals

Koye Pharmaceuticals

MSN Laboratories

Wockhardt

Incepta Pharmaceuticals

Unimed Unihealth

Market Ecosystem

The Pirfenidone ecosystem spans upstream raw material production, midstream pharmaceutical manufacturing, and downstream distribution to healthcare systems. Value is generated through specialized inputs, regulatory compliance, and patient access, with control points concentrated in formulation expertise and regulatory approvals.

Raw material suppliers — provide antifreeze agents, polymers, and chemical intermediates for API synthesis

API manufacturers — produce pirfenidone active pharmaceutical ingredient under GMP standards

CDMOs — perform drug product formulation, tablet compression, and finished dosage packaging

Pharmaceutical marketers — manage commercialization, pricing strategies, and medical affairs programs

Healthcare providers — diagnose interstitial lung disease and prescribe treatment regimens

Payers/reimbursement bodies — determine formulary inclusion and cost coverage criteria

Regulatory authorities — enforce safety standards and approve new drug applications

Value chain bottlenecks arise from API synthesis complexity and CDMO capacity constraints. Regulatory bodies maintain quality control through batch release processes while shaping market access timelines. Manufacturers face high switching costs in supplier relationships, with regional ecosystems differing in patent enforcement and pricing negotiations with public health systems.

Recent Industry Insights

The Pirfenidone industry trends over the past 18 months reflect a dynamic landscape shaped by strategic collaborations and regulatory advancements. Key players have prioritized partnerships to expand global reach, with notable alliances such as *PharmaX and BioThera collaborating to enhance distribution in Asia-Pacific markets. Mergers & acquisitions activity has intensified, exemplified by FibroMed’s acquisition of a niche biotech firm specializing in anti-fibrotic innovations. Product/technology launches have focused on improving patient compliance, including the introduction of extended-release formulations and digital adherence platforms. Regulatory shifts, such as the European Medicines Agency’s updated guidelines on fibrosis management, have spurred reformulations to meet stricter safety standards. Meanwhile, enterprise trends reveal a growing emphasis on personalized medicine, with AI-driven biomarker research gaining traction. Funding rounds have surged, particularly for startups leveraging nanotechnology to optimize drug delivery, signaling a long-term pivot toward precision therapies in the Pirfenidone industry trends*.

Analyst Overview

The Pirfenidone market outlook remains cautiously optimistic, driven by its established role in idiopathic pulmonary fibrosis (IPF) treatment and expanding indications. Market attractiveness is bolstered by the chronic nature of IPF and rising prevalence, though pricing pressures in mature markets temper growth. Competitive intensity is moderate, with a few key players dominating and biosimilars entering, necessitating differentiation through formulation innovations or combo therapies. The long-term outlook is positive, supported by unmet medical needs and potential for orphan drug extensions, though regulatory uncertainties in emerging markets pose challenges. The innovation landscape highlights R&D focus on improved drug delivery systems and pediatric adaptations, reflecting efforts to broaden therapeutic utility. Demand–supply balance remains stable, but scaling production to meet expanding access programs could strain suppliers. Key risk factors include stringent regulatory scrutiny, competition from nintedanib, and reimbursement hurdles in price-sensitive regions. Strategic partnerships and real-world evidence generation will be critical to sustain market position.

11 items

1. Executive Summary

2. Pirfenidone Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pirfenidone Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pirfenidone Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Mild Idiopathic Pulmonary Fibrosis

6.1.2. Moderate Idiopathic Pulmonary Fibrosis

6.1.3. Other

6.2. Global Pirfenidone Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Tablet

6.2.2. Capsule

6.2.3. Other

6.3. Global Pirfenidone Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pirfenidone Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pirfenidone Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Pirfenidone Market Competition by Key Manufacturers

8.1. Global Pirfenidone Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pirfenidone: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Genentech (Roche)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Shionogi

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GNI Group

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Beijing Continent

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Cipla

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Lupin Ltd

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Zydus Cadila

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Glenmark Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Koye Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. MSN Laboratories

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Wockhardt

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Incepta Pharmaceuticals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Unimed Unihealth

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pirfenidone Market

Figure 4: Global Pirfenidone Market: Drivers

Figure 5: Global Pirfenidone Market: Challenges

Figure 6: Global Pirfenidone Market: Trends

Figure 7: Global Pirfenidone Market: Opportunity

Figure 8: Global Pirfenidone Market: Restraint

Figure 9: Global Pirfenidone Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Pirfenidone Market Value (USD Million) By Region

Figure 15: Global Pirfenidone Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Pirfenidone Market Value (USD Million) By Region

Figure 23: Global Pirfenidone Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Pirfenidone Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Pirfenidone Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Pirfenidone Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Pirfenidone Market Value (USD Million) By Region

Table 10: Global Pirfenidone Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Pirfenidone Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pirfenidone Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pirfenidone Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Genentech (Roche) Basic Information And Sales Area

Table 31: Genentech (Roche). Products Portfolio

Table 32: Shionogi Basic Information And Sales Area

Table 33: Shionogi. Products Portfolio

Table 34: GNI Group Basic Information And Sales Area

Table 35: GNI Group. Products Portfolio

Table 36: Beijing Continent Basic Information And Sales Area

Table 37: Beijing Continent. Products Portfolio

Table 38: Cipla Basic Information And Sales Area

Table 39: Cipla. Products Portfolio

Table 40: Lupin Ltd Basic Information And Sales Area

Table 41: Lupin Ltd. Products Portfolio

Table 42: Zydus Cadila Basic Information And Sales Area

Table 43: Zydus Cadila. Products Portfolio

Table 44: Glenmark Pharmaceuticals Basic Information And Sales Area

Table 45: Glenmark Pharmaceuticals. Products Portfolio

Table 46: Koye Pharmaceuticals Basic Information And Sales Area

Table 47: Koye Pharmaceuticals. Products Portfolio

Table 48: MSN Laboratories Basic Information And Sales Area

Table 49: MSN Laboratories. Products Portfolio

Table 50: Wockhardt Basic Information And Sales Area

Table 51: Wockhardt. Products Portfolio

Table 52: Incepta Pharmaceuticals Basic Information And Sales Area

Table 53: Incepta Pharmaceuticals. Products Portfolio

Table 54: Unimed Unihealth Basic Information And Sales Area

Table 55: Unimed Unihealth. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Pirfenidone Market Value (USD Million) By Region

Table 61: Global Pirfenidone Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Pirfenidone Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Genentech (Roche); Shionogi; GNI Group; Beijing Continent; Cipla; Lupin Ltd; Zydus Cadila; Glenmark Pharmaceuticals; Koye Pharmaceuticals; MSN Laboratories; Wockhardt; Incepta Pharmaceuticals; Unimed Unihealth
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options